Bamco Inc. NY bought a new position in shares of Emergent Biosolutions Inc (NYSE:EBS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 45,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,091,000. Bamco Inc. NY owned about 0.09% of Emergent Biosolutions as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of EBS. Renaissance Technologies LLC lifted its stake in Emergent Biosolutions by 37.5% during the fourth quarter. Renaissance Technologies LLC now owns 1,584,911 shares of the biopharmaceutical company’s stock worth $73,651,000 after purchasing an additional 432,300 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in Emergent Biosolutions during the fourth quarter worth approximately $16,448,000. OppenheimerFunds Inc. lifted its stake in Emergent Biosolutions by 3,271.5% during the fourth quarter. OppenheimerFunds Inc. now owns 331,758 shares of the biopharmaceutical company’s stock worth $15,417,000 after purchasing an additional 321,918 shares during the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in Emergent Biosolutions during the fourth quarter worth approximately $10,300,000. Finally, Snyder Capital Management L P lifted its stake in Emergent Biosolutions by 13.1% during the fourth quarter. Snyder Capital Management L P now owns 1,242,521 shares of the biopharmaceutical company’s stock worth $57,740,000 after purchasing an additional 144,332 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.
Several research firms recently weighed in on EBS. Goldman Sachs Group began coverage on Emergent Biosolutions in a research note on Wednesday, January 24th. They set a “neutral” rating and a $55.00 target price for the company. Singular Research boosted their price objective on Emergent Biosolutions from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. ValuEngine upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Zacks Investment Research cut Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, February 26th. Finally, Chardan Capital boosted their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $52.80.
Shares of Emergent Biosolutions Inc (EBS) opened at $52.49 on Monday. The company has a quick ratio of 3.42, a current ratio of 4.85 and a debt-to-equity ratio of 0.01. Emergent Biosolutions Inc has a 52 week low of $27.94 and a 52 week high of $52.84. The firm has a market capitalization of $2,590.00, a P/E ratio of 32.20, a price-to-earnings-growth ratio of 1.02 and a beta of 1.26.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.04. Emergent Biosolutions had a return on equity of 13.66% and a net margin of 14.73%. The company had revenue of $193.80 million during the quarter, compared to analysts’ expectations of $189.96 million. During the same quarter in the previous year, the business earned $0.74 earnings per share. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. equities research analysts expect that Emergent Biosolutions Inc will post 2.33 EPS for the current year.
In other news, Director Ronald Richard sold 23,681 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $45.02, for a total value of $1,066,118.62. Following the transaction, the director now owns 47,091 shares of the company’s stock, valued at $2,120,036.82. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Adam Havey sold 1,898 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $49.50, for a total value of $93,951.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,637 shares of company stock valued at $3,391,674. 16.50% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Bamco Inc. NY Buys New Position in Emergent Biosolutions Inc (EBS)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://ledgergazette.com/2018/03/12/bamco-inc-ny-buys-new-position-in-emergent-biosolutions-inc-ebs.html.
Emergent Biosolutions Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.